NO20021835D0 - Tricykliske forbindelser anvendelige som HIV-reverse transkriptaseinhibitorer - Google Patents

Tricykliske forbindelser anvendelige som HIV-reverse transkriptaseinhibitorer

Info

Publication number
NO20021835D0
NO20021835D0 NO20021835A NO20021835A NO20021835D0 NO 20021835 D0 NO20021835 D0 NO 20021835D0 NO 20021835 A NO20021835 A NO 20021835A NO 20021835 A NO20021835 A NO 20021835A NO 20021835 D0 NO20021835 D0 NO 20021835D0
Authority
NO
Norway
Prior art keywords
reverse transcriptase
compounds useful
transcriptase inhibitors
hiv reverse
tricyclic compounds
Prior art date
Application number
NO20021835A
Other languages
English (en)
Other versions
NO20021835L (no
Inventor
Barry L Johnson
Mona Patel
James David Rodgers
Haisheng Wang
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20021835D0 publication Critical patent/NO20021835D0/no
Publication of NO20021835L publication Critical patent/NO20021835L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20021835A 1999-10-19 2002-04-18 Tricykliske forbindelser nyttige som HIV-reverse transkriptase inhibitorer NO20021835L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16032999P 1999-10-19 1999-10-19
US22617100P 2000-08-17 2000-08-17
PCT/US2000/028824 WO2001029037A2 (en) 1999-10-19 2000-10-19 Condensed naphthyridines as hiv reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
NO20021835D0 true NO20021835D0 (no) 2002-04-18
NO20021835L NO20021835L (no) 2002-06-18

Family

ID=26856799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021835A NO20021835L (no) 1999-10-19 2002-04-18 Tricykliske forbindelser nyttige som HIV-reverse transkriptase inhibitorer

Country Status (19)

Country Link
US (2) US6593337B1 (no)
EP (1) EP1222186A2 (no)
JP (1) JP2003512375A (no)
KR (1) KR20020079729A (no)
CN (1) CN1409711A (no)
AU (1) AU773309B2 (no)
BR (1) BR0015056A (no)
CA (1) CA2387896A1 (no)
CZ (1) CZ20021353A3 (no)
EA (1) EA200200471A1 (no)
EE (1) EE200200202A (no)
HK (1) HK1049150A1 (no)
HU (1) HUP0300190A2 (no)
IL (1) IL149219A0 (no)
MX (1) MXPA02003958A (no)
NO (1) NO20021835L (no)
PL (1) PL355727A1 (no)
SK (1) SK5342002A3 (no)
WO (1) WO2001029037A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
MXPA03009482A (es) * 2001-04-19 2004-02-12 Bristol Myers Squibb Co Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih).
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc METHOD AND APPARATUS FOR PROVIDING IMPROVED SAMPLE CAPTURING DEVICE
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND APPARATUS PROVIDING A VARIABLE USER INTERFACE
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US7504969B2 (en) * 2006-07-11 2009-03-17 Data Domain, Inc. Locality-based stream segmentation for data deduplication
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
JP5643290B2 (ja) * 2009-04-09 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｉｖ複製の阻害薬
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2012092367A1 (en) * 2010-12-28 2012-07-05 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262294D1 (en) 1981-05-13 1985-03-28 Ici Plc Pharmaceutical compositions containing spiro succinimide derivatives
DD204480A1 (de) 1982-04-13 1983-11-30 Meisel Verfahren zur herstellung von in 10-stellung basisch substituierten 5,5-dimethyl-5,10-dihydro-benzo(b)(1,8)naphthyridinen
EP0393604B1 (en) 1989-04-20 1997-12-29 Boehringer Ingelheim Pharmaceuticals Inc. 6,11-Dihydro-5H-pyrido(2,3-b)(1,5,)benzodiazepin-5-ones and thiones and their use in the prevention or treatment of AIDS
ATE116320T1 (de) 1989-04-20 1995-01-15 Boehringer Ingelheim Pharma 5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin 6-one und -thione und deren verwendung bei der vorbeugung und und behandlung von aids.
US5171745A (en) 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
US5087625A (en) 1990-10-19 1992-02-11 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridodiazepines and their use in the prevention or treatment of HIV infection
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
HUT71132A (en) 1992-03-27 1995-11-28 Schering Corp Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2145407C (en) 1992-09-28 2009-09-22 Louis A. Carpino New reagents for peptide couplings
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
WO1995012583A1 (en) 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
DE4344452A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
WO1996031469A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5874430A (en) 1996-10-02 1999-02-23 Dupont Pharmaceuticals Company 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
NO20021835L (no) 2002-06-18
WO2001029037A2 (en) 2001-04-26
US20040002498A1 (en) 2004-01-01
KR20020079729A (ko) 2002-10-19
CZ20021353A3 (cs) 2002-09-11
HUP0300190A2 (en) 2003-05-28
PL355727A1 (en) 2004-05-17
WO2001029037A3 (en) 2002-01-24
AU1213701A (en) 2001-04-30
SK5342002A3 (en) 2003-04-01
EP1222186A2 (en) 2002-07-17
MXPA02003958A (es) 2002-12-10
CN1409711A (zh) 2003-04-09
IL149219A0 (en) 2002-11-10
EA200200471A1 (ru) 2003-04-24
HK1049150A1 (zh) 2003-05-02
EE200200202A (et) 2003-06-16
JP2003512375A (ja) 2003-04-02
AU773309B2 (en) 2004-05-20
BR0015056A (pt) 2003-06-10
CA2387896A1 (en) 2001-04-26
US6593337B1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
NO20021835L (no) Tricykliske forbindelser nyttige som HIV-reverse transkriptase inhibitorer
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20021042D0 (no) Benzofenoner som inhibitorer av revers transkriptase
NO20031672L (no) Aza- og polyazanaftalenylkarboksamid-derivater anvendbare som HIV-integraseinhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
NO20013909L (no) Heteroaryl-substituerte kinolin-2-on derivater nyttige som anticancer midler
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20006071L (no) Isotiazolderivater nyttige som anti-cancer midler
NO20043174L (no) Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer
DK1007520T3 (da) 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer
NO20032531D0 (no) Tetralon-derivater som antitumormidler
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
DK1355900T3 (da) Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
NO20021407D0 (no) Bifenylderivater anvendt som NHE-3-inhibitorer
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20043424L (no) Tricykliske 2-pyrimidon forbindelser nyttige som HIV revers transkriptase inhibitorer
DK1086097T3 (da) Sulfonylbenzenforbindelser som anti-inflammatoriske/analgetiske midler
MXPA03009482A (es) Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih).
ATE322492T1 (de) Nicht-nukleosid reverse transkriptase inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application